# Human Cerebral Blood Flow Regulation

> **NCT04265053** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 110 (actual)

## Conditions studied

- Cerebral Arterial Diseases

## Interventions

- **DRUG:** Indomethacin 25 MG/50 MG
- **DRUG:** Placebo - Lactose
- **DRUG:** Ganirelix Acetate
- **DRUG:** Testosterone Transdermal Product
- **DRUG:** Estradiol Topical
- **DRUG:** Antacid

## Key facts

- **NCT ID:** NCT04265053
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265053, "Human Cerebral Blood Flow Regulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04265053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*